Estimation of partial agonist affinity by interaction with a full agonist: a direct operational model-fitting...

Area of Science:

• Pharmacology
• Receptor Theory
• Computational Biology

Background:

• The operational model of agonism provides a framework for understanding drug-receptor interactions.
• Analyzing interactions between full and partial agonists is crucial for drug development and understanding receptor pharmacology.
• Existing methods for estimating partial agonist affinity can be complex and time-consuming.

Purpose of the Study:

• To extend the operational model of agonism to quantitatively describe interactions between partial and full agonists at the same receptor.
• To develop a method for directly estimating the affinity and efficacy of partial agonists from experimental concentration-effect data.
• To compare the efficacy of the extended operational model with the conventional null method for analyzing agonist interactions.

Main Methods:

• Extended the operational model of agonism to derive an equation for full/partial agonist interactions.
• Applied the derived equation to analyze experimental agonist concentration-effect (E/[A]) curve data.
• Used pilocarpine (partial agonist) and carbachol (full agonist) interactions at M3-muscarinic receptors in guinea-pig trachea.
• Compared affinity estimates obtained from operational model-fitting with those from the null method.

Main Results:

• The extended operational model accurately describes the interaction between partial and full agonists.
• Direct fitting of E/[A] data using the operational model allowed for straightforward estimation of pilocarpine affinity.
• Operational model-fitting and null method yielded comparable affinity estimates (mean pKB: 5.79 vs. 5.86).
• Simultaneous fitting of multiple partial agonist concentrations revealed the competitive nature of the interaction.

Conclusions:

• Operational model-fitting is a valid and analytically simple alternative to the null method for analyzing full/partial agonist interactions.
• This extended model provides a robust tool for characterizing partial agonists.
• The findings simplify the quantitative analysis of complex agonist-receptor dynamics.